Destiny Pharma (LON:DEST) Hits New 52-Week Low at $7.60

Shares of Destiny Pharma plc (LON:DEST) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 7.60 ($0.10) and last traded at GBX 8.65 ($0.11), with a volume of 401292 shares traded. The stock had previously closed at GBX 8.50 ($0.11).

Wall Street Analyst Weigh In

Separately, Shore Capital reissued a “house stock” rating on shares of Destiny Pharma in a research report on Wednesday, June 12th.

Destiny Pharma Price Performance

The company’s 50-day moving average price is GBX 14.41 and its 200-day moving average price is GBX 34.64. The company has a market cap of £7.77 million, a P/E ratio of -141.67 and a beta of 0.31.

Destiny Pharma Company Profile

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.